First kind: approved medicine
A finished medicine with a named use
As of September 2026, medicines approved by the US Food and Drug Administration (FDA), the government agency that approves medicines, included two peptides known by their generic names: semaglutide, marketed under the names Ozempic and Wegovy, and tirzepatide, marketed under the names Mounjaro and Zepbound. Ozempic and Mounjaro are approved to help adults with type 2 diabetes control their blood sugar. Wegovy and Zepbound are approved for weight loss and keeping the weight off.
Approval covers one specific product for the specific illness or purpose it was approved for. It does not cover every product that shares the word “peptide.”